Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellula...
Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial
About this item
Full title
Author / Creator
Publisher
England: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
The third interim results of the START trial showed encouraging safety and efficacy profiles, with a median time to progression of 9 months. This subgroup analysis presents results in Chinese patients enrolled in the START trial.
Sixty two Chinese patients (median age 52 years) with unresectable hepatocellular carcinoma had transarterial chemoem...
Alternative Titles
Full title
Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1315630067
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1315630067
Other Identifiers
ISSN
1479-6694
E-ISSN
1744-8301
DOI
10.2217/fon.13.11
